北京时间·🕒 发布 19:01:35·⟳ 抓取 19:03:00 +1m25s·⚡ 决策 08-28 21:25:03 +2h22m·60.3 天前
This earnings report is a mixed signal of 'low growth on the surface + Q2 sequential decline + dividend announcement'. The headline YoY +1.88% itself cannot determine whether it beat, met, or missed consensus expectations. Q2 net profit dropped 18% QoQ, but the seasonal pattern has not been verified. Furthermore, the segment breakdown and management outlook have not been read. There is no clear strong catalyst in either direction. Neither long nor short has positive expected value, so AVOID.
📄 原文财联社电报↗ 原文
云南白药：上半年净利润37.01亿元 同比增长1.88%
【云南白药：上半年净利润37.01亿元 同比增长1.88%】财联社8月28日电，云南白药(000538.SZ)公告称，公司发布2026年半年度报告，实现营业收入218.84亿元，同比增长2.95%；归属于上市公司股东的净利润37.01亿元…
不做 云南白药（000538.SZ）
Half-year report shows low growth (net profit +1.88%) + Q2 sequential decline of 18%, but comparison with market expectations is unknown, segment breakdown and decline reason are missing, and the direction cannot be determined; the positiv…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
展开后加载成交明细、研究档案、原文全文与决策记录链。